🇺🇸 SODIUM PHENYLACETATE in United States

45 US adverse-event reports

Marketing authorisation

FDA

  • Status: approved

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Drug Ineffective — 16 reports (35.56%)
  2. Drug Ineffective For Unapproved Indication — 5 reports (11.11%)
  3. Off Label Use — 4 reports (8.89%)
  4. Ammonia Increased — 3 reports (6.67%)
  5. Hyperammonaemia — 3 reports (6.67%)
  6. Hyperammonaemic Encephalopathy — 3 reports (6.67%)
  7. Myelosuppression — 3 reports (6.67%)
  8. Respiratory Alkalosis — 3 reports (6.67%)
  9. Status Epilepticus — 3 reports (6.67%)
  10. Condition Aggravated — 2 reports (4.44%)

Source database →

SODIUM PHENYLACETATE in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Frequently asked questions

Is SODIUM PHENYLACETATE approved in United States?

Yes. FDA has authorised it.

Who is the marketing authorisation holder for SODIUM PHENYLACETATE in United States?

Marketing authorisation holder not available in our data.